Cue Biopharma shares rose about 9.5% in premarket trading on November 18, 2026. The move followed a 79.9% decline the previous day.
The sell-off came after the company released its third-quarter results following the market close on November 16. Cue reported a net loss of $50.0 million, or $4.74 per share. That compared with a net loss of $7.4 million in the same period a year earlier.
The results appeared to drive the sell-off and subsequent volatility. Cue made no specific announcement on November 18 to explain the premarket rebound, which may have reflected a technical reaction to the prior day's sharp decline.